Provides company with the continued ability to move quickly and decisivelyCHARLOTTE, N.C., April 16, 2025 (GLOBE NEWSWIRE) -- ...

It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as ...

Single-point mutations within the kinase domain of BCR–ABL constitute the most frequent cause of acquired resistance to ABL kinase inhibitors in patients with chronic myeloid leukaemia (CML ...

BCR-ABL point mutants resistant to the second generation ... In normal tissues, the expression of Aurora C kinase is predominantly restricted to germ cells, although the function of this enzyme ...

The Amended ABL Facility remains at $100 million and was, among other things, extended by over three years to April 2030. The Amended ABL Facility will bear interest at a rate equal to the forward ...